Related Experiment Video
Updated: Oct 17, 2025
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical
Anneke D van Dijk1, Ti'ara L Griffen2, Yihua H Qiu3
1Department of Pediatric Oncology/Hematology, University Medical Center Groningen, Groningen, the Netherlands. a.d.van.dijk@umcg.nl.
Abstract:
The chronic lymphocytic leukemia (CLL) armamentarium has evolved significantly, with novel therapies that inhibit Bruton Tyrosine Kinase, PI3K delta and/or the BCL2 protein improving outcomes. Still, the clinical course of CLL patients is highly variable and most previously recognized prognostic features lack the capacity to predict response to modern treatments indicating the need for new prognostic markers. In this study, we identified four epigenetically distinct proteomic signatures of a large cohort of CLL and related diseases derived samples (n = 871) using reverse phase protein array technology. These signatures are associated with clinical features including age, cytogenetic abnormalities [trisomy 12, del(13q) and del(17p)], immunoglobulin heavy-chain locus (IGHV) mutational load, ZAP-70 status, Binet and Rai staging as well as with the outcome measures of time to treatment and overall survival. Protein signature membership was identified as predictive marker for overall survival regardless of other clinical features. Among the analyzed epigenetic proteins, EZH2, HDAC6, and loss of H3K27me3 levels were the most independently associated with poor survival. These findings demonstrate that proteomic based epigenetic biomarkers can be used to better classify CLL patients and provide therapeutic guidance.
Insights
New proteomic signatures identify distinct epigenetic profiles in chronic lymphocytic leukemia (CLL). These biomarkers predict patient survival, offering improved prognostic guidance beyond traditional markers for CLL.
Area of Science:
- Oncology
- Proteomics
- Epigenetics
Background:
- Chronic lymphocytic leukemia (CLL) treatment has advanced with targeted therapies.
- Existing prognostic markers for CLL often fail to predict responses to modern treatments.
- There is a critical need for novel prognostic markers in CLL management.
Purpose of the Study:
- To identify novel, epigenetically distinct proteomic signatures in CLL.
- To assess the association of these signatures with clinical features and outcomes.
- To evaluate the utility of proteomic biomarkers for predicting CLL patient survival.
Main Methods:
- Utilized reverse phase protein array technology on a large cohort of CLL samples (n=871).
- Analyzed proteomic signatures in relation to clinical parameters (age, cytogenetics, IGHV, ZAP-70, staging).
- Assessed the predictive value of protein signatures for time to treatment and overall survival.
Main Results:
- Identified four epigenetically distinct proteomic signatures in CLL.
- These signatures correlated with various clinical features and prognostic indicators.
- Protein signature membership independently predicted overall survival in CLL patients.
- Specific epigenetic proteins (EZH2, HDAC6, H3K27me3) were linked to poor survival.
Conclusions:
- Proteomic-based epigenetic biomarkers can effectively classify CLL patients.
- These biomarkers offer improved prognostic stratification and therapeutic guidance.
- Novel proteomic signatures enhance the understanding of CLL heterogeneity and progression.
